This draft guidance provides a risk-based framework for evaluating the quality of container closure systems (CCSs) used with human drugs and biological products, including quality assessments and quality control of packaging materials and components. It applies to new applications, amendments, supplements, and legally marketed drugs under section 505G, and FDA... The post Container Closure Systems for Human Drugs and Biological Products appeared first on Avance Biosciences .